Wild-type p53-induced phosphatase sensitizes acute myeloid leukemia cells to conventional chemotherapy

Recently wild-type p53-induced phosphatase was implicated in the pathogenesis of acute myeloid leukemia (AML) and “pre-leukemia” myeloproliferative conditions. Here we decided to check how strategy directed inhibition affected sensitivity conventional chemotherapy. All experiments were conducted on AML cell lines cultivated vitro. The levels vary different lines. chemical compound GSK2830371 reduced diminished its activity. did not significantly change cycle distribution cells when used alone or combination with anti-cancer chemotherapeutic drug Cytosar but increased caspase-dependent PARP1 cleavage. In contrast previous studies, observe negative effect activity depletion a inhibitor as monotherapy. Using able reduce threshold chemotherapy-dependent cytotoxicity more efficiently eliminate leukemic cells. We propose considering prospective improving anti-AML therapy.